Peer Review History
| Original SubmissionApril 28, 2020 |
|---|
|
GCN sensitive protein translation in yeast PONE-D-20-12392 Dear Dr. Weir, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Arthur J. Lustig Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The paper by Barr et al. shows an elaborated example for research spanning various disciplines, bringing together molecular dynamics, bioinformatics and wet-lab biochemistry - each technically very thorough. The conclusions drawn are well-based and elucidate a phenomenon so far little understood. Reviewer #2: The manuscript by Barr et al. is devoted to the discovery and study of the mechanism of mRNA translation regulation, mediated by overrepresentation of GCN codons in the initial section of ORFs (so-called ramp region). The authors make a counter-intuitive observation that while GCN periodicity is pronounced in mRNA of genes with high expression, its de novo artificial introduction into the ramp sequence reduces the translation efficiency. Adequacy of the contribution of GCN codons representation to the translation level of the model genes’ (SKN7 and HMT1 and their sequence-altered variants) mRNA is proved by the scrupulous control experiments aimed at the transcription efficiency and protein stability measurements as well as the normalized translation efficiency scoring. The authors put forward a theory that translation levels inversely correlate with ramp GCN periodicity, confirming it not only with their model experiments on a pair of yeast genes, but also with the analysis of large-scale data previously published by other groups studying the role of the ramp region in translation efficiency. Finally, the authors propose a mechanistic model for the interaction of ribosome with mRNA (CAR-mRNA), which explains the regulatory principle of GCN periodicity (metaphorically described as the accelerator and braking system for ribosome translation). It was a pleasure for me to read this manuscript. In form and in content significance, it recalls the classic papers of the 60-70s on the discovery of the basic principles of molecular biology. It is surprising that such fundamental and seemingly self-explanatory aspect of gene expression will be included in the coursebooks only in the third decade of the 21st century. Undoubtedly, the theory proposed by the authors requires further testing of its applicability on the larger gene cohorts and within the translation systems of different organisms. Also these results call for the structural studies of the CAR-mRNA interface. However, to my mind the need for further development of this topic does not detract from the contribution already made by Barr et al. team. I would strongly recommend this manuscript for publication as it is. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Andreas Savelsbergh Reviewer #2: No |
| Formally Accepted |
|
PONE-D-20-12392 GCN sensitive protein translation in yeast Dear Dr. Weir: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Arthur J. Lustig Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .